ADVBHealthcare · Diagnostics & ResearchADVB Stock Forecast: Advanced Biomed, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 4 Nov 2026 — in the weakest quartile.
ADVB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Advanced Biomed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Growth (6): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ADVB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ADVB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
ADVB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ADVB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Advanced Biomed, Inc. returned −77.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ADVB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Advanced Biomed, Inc. (ADVB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.1×
- Price / sales
- 28.5×
- Price / book
- 0.3×
- EV / EBITDA
- −0.7×
Cheaper than 70% of US stocks
Cheaper than 7% of US stocks
Cheaper than 86% of US stocks
Cheaper than 68% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −3856.4%
- Net margin
- 5231.3%
Higher than 3% of US stocks
Higher than 99% of US stocks
- Return on equity
- −79.5%
- Return on assets
- −21.3%
- Dividend yield
- 0.0%
Higher than 16% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Advanced Biomed, Inc. (ADVB) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Advanced Biomed, Inc. has a market value of $3.6M and an enterprise value of $4.3M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: $4.6M.
Diluted earnings per share, trailing twelve months: $4.02.
Free cash flow in the twelve months to 31 Mar 2026: −$4.8M, after $18K of capital spending.
Trailing P/E: 1.1×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Advanced Biomed, Inc. employs 12 people.
Data provided by Twelve Data
ADVB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Advanced Biomed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ADVB stock
How does Ticker Nerd's model rank ADVB?
As at 4 Nov 2026, Advanced Biomed, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the ADVB stock forecast for 2030?
No analyst covering Advanced Biomed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADVB are extrapolating price history, which says nothing about the business.
How has ADVB stock performed over the past year?
Advanced Biomed, Inc. returned -77.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Advanced Biomed, Inc. do?
Advanced Biomed Inc. is a medical technology holding company focused on microfluidic biochip technologies for cancer diagnostics and precision oncology.
About Advanced Biomed, Inc.
Advanced Biomed Inc. is a medical technology holding company focused on microfluidic biochip technologies for cancer diagnostics and precision oncology. The company develops assay products and laboratory solutions used in early screening, detection, diagnosis, staging, and treatment support for cancer patients. Its product portfolio includes automated sample preparation systems, circulating tumor cell capture devices, rare cell analysis tools, immunostaining kits, and lung cancer early screening kits. Advanced Biomed Inc. also provides related biochips and analyzer systems that combine semiconductor technology with biotechnology to support clinical and research workflows. The company serves healthcare and diagnostic applications across Taiwan and other markets, with an emphasis on improving the accuracy and efficiency of oncology testing. Headquartered in Tainan, Taiwan, Advanced Biomed Inc. operates as a specialized player in the healthcare and biotechnology sector.
CEO Mr. Xiaomin Chen Ph.D. · 12 employees · Hong Kong · https://www.advb.ai